Pyrido[2,3-D]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Abstract

compound JPEG2022537047000061.jpg59155 and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are disclosed.

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present invention relates to compounds, compositions and methods for the treatment of human immunodeficiency virus (HIV) infection. More particularly, the present invention provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods of using these compounds in the treatment of HIV infection. The present invention also relates to methods of making the compounds described below. [Background technology]

[0002] 2. Background of the Invention Acquired immune deficiency syndrome (AIDS) is the result of infection with HIV. HIV remains a major global public health problem. In 2015, an estimated 36.7 million people were living with HIV (including 1.8 million children), giving a global HIV prevalence of 0.8%. The majority of this number live in low- and middle-income countries. In the same year, 1.1 million people died from AIDS-related illnesses.

[0003] Current therapy for HIV-infected individuals consists of a combination of approved antiretroviral agents. Nearly 48 drugs are currently approved for HIV infection, either as single agents, fixed-dose combinations, or single-pill regimens, the latter two containing 2-4 approved agents. These agents belong to a number of different classes that target either viral enzymes or the function of viral proteins during the viral replication cycle. Thus, agents are classified as either nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), or entry inhibitors (one, maraviroc, targets the host CCR5 protein, and the other, enfuvirtide, a peptide that targets the gp41 region of the viral gp160 protein). Additionally, pharmacokinetic enhancers (cobicistat or ritonavir) can be used in combination with antiretrovirals (ARVs) that require boosting.

[0004] Despite the availability of drug and drug combination treatments, there remains a medical need for new antiretroviral agents. High viral heterogeneity, drug-related toxicity, tolerability issues, and poor adherence can all lead to treatment failure and to the selection of viruses harboring mutations that confer resistance to one or more antiretroviral agents from across classes, or even to multiple agents (Beyrer, C., Pozniak A. HIV drug resistance - an emerging threat to epidemic control. N. Engl. J. Med. 2017, 377, 1605-1607; Gupta, RK, Gregson J., et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect. Dis. 2017, 18, 346-355; Zazzi, M., Hu, H., Prosperi, M. The global burden of HIV-1 drug resistance in the past 20 years. years. PeerJ. 2018, DOI 10.7717 / peerj.4848). As a result, there is a need for novel agents that are easy to take, have a high genetic barrier to the development of resistance, and have improved safety over current agents. In this set of choices, novel mechanisms of action (MOAs) that can be used as part of the preferred antiretroviral therapy (ART) may still have a major role to play, as they should be effective against viral resistance to current agents. Improvements that would make the agent easier to take for a long time or even lifelong may include all or some of the following: fewer side effects, fewer drug-drug interactions, increased time between doses, or alternative routes of administration to match individual patient preferences.The objective of improving safety would certainly include a high therapeutic index against any toxicity that would cause discontinuation of administration, and may also include reduced side effects or reduced drug-drug interactions. The possibility of using fewer overall drugs in combination regimens would also likely result in improved compliance and safety. Increased efficacy against antiviral targets would also lead to dose reductions, especially when maintained in the presence of human plasma and serum albumin, and may have a direct and positive impact on the duration of administration and therapeutic index over side effects and toxicity. In summary, the discovery of anti-HIV drugs with novel mechanisms of action that also have the other benefits mentioned above that promote long-term compliance and safety would achieve maximum benefit to HIV-infected patients.

[0005] Certain potentially therapeutic compounds have now been described in the art and are described in Blair, Wade S. et. al. Antimicrobial Agents and Chemotherapy (2009), 53(12), 5080-5087, Blair, Wade S. et al. PLoS Pathogens (2010), 6(12), e1001220, Thenin-Houssier, Suzie; Valente, Susana T. Current HIV Research, 2016, 14, 270-282, as well as the following numbered PCT patent applications: WO2012065062, WO2013006738, WO2013006792, WO2014110296, WO2014110297, WO2014110298, WO2014134566, WO2015130964, WO2015130966, WO2016033243, WO2018035359, and WO2018203235.

[0006] What is currently needed in the art are new and useful compounds for the treatment of HIV.Furthermore, these compounds should provide pharmaceutical use advantages, for example, in terms of one or more of their mechanism of action, binding, inhibitory efficacy, target selectivity, solubility, safety profile, bioavailability and / or reduced administration frequency.New formulations and methods of treatment utilizing these compounds are also needed. Summary of the Invention

[0007] Briefly, in one aspect, the present invention provides a compound as shown below: [ka] and pharma- ceutically acceptable salts thereof (hereinafter "the compounds and salts of the invention").

[0008] In another aspect, the present invention discloses a pharmaceutical composition comprising a compound or salt of the present invention.

[0009] In another aspect, the invention discloses a method of treating HIV infection in a human comprising administering a compound or salt of the invention.

[0010] In another aspect, the present invention discloses a compound or salt of the present invention for use in therapy.

[0011] In another aspect, the present invention discloses a compound or salt of the present invention for use in the treatment of HIV infection in a human.

[0012] In another aspect, the invention discloses the use of a compound or salt of the invention in the manufacture of a medicament for the treatment of HIV infection in a human. [Brief description of the drawings]

[0013] [Figure 1] FIG. 1 summarizes the mean plasma concentration time profiles in rats from the studies described below. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] Detailed Description of the Invention Preferably, the compounds and salts of the present invention have the stereochemistry shown below. [ka]

[0015] In another aspect, the compounds and salts of the invention have the stereochemistry shown below. [ka]

[0016] The salts of the present invention are pharma- ceutically acceptable. Such salts may be acid addition salts or base addition salts. For a review of suitable pharma-ceutically acceptable salts, see, for example, Berge et al, J. Pharm, Sci., 66, 1-19, 1977.

[0017] Representative pharma- ceutically acceptable acid addition salts include, but are not limited to, 4-acetamidobenzoate, acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate (besylate), benzoate, bisulfate, bitartrate, butyrate, calcium edetate, camphorate, camphorsulfonate (camsylate), caprate (decanoate), caproate (hexanoate), caprylate (octanoate), cinnamate, citrate, cyclamate, digluconate, 2,5-dihydroxybenzoate, and disuccinate. Salt, dodecyl sulfate (estolate), edetate (ethylenediaminetetraacetate), estolate (lauryl sulfate), ethane-1,2-disulfonate (edisylate), ethanesulfonate (esylate), formate, fumarate, galactarate (mucate), gentisate (2,5-dihydroxybenzoate), glucoheptonate (glucoceptate), gluconate, glucuronate, glutamate, glutarate, glycerophosphate, glycolate, hexylresorcinate, hippurate, hyaluronate ... Drabamine (N,N'-di(dehydroabietyl)-ethylenediamine), hydrobromide, hydrochloride, hydroiodide, hydroxynaphthoate, isobutyrate, lactate, lactobionate, laurate, malate, maleate, malonate, mandelate, methanesulfonate (mesylate), methylsulfate, mucate, naphthalene-1,5-disulfonate (napadisylate), naphthalene-2-sulfonate (napsylate), nicotinate, nitrate, oleate, palmitate, p-aminobenzenesulfonate, p-aminosalicylate , pamoate (embonate), pantothenate, pectinate, persulfate, phenylacetate, phenylethylbarbiturate, phosphate, polygalacturonate, propionate, p-toluenesulfonate (tosylate), pyroglutamate, pyruvate, salicylate, sebacate, stearate, subacetate, succinate, sulfamate, sulfate, tannate, tartrate, theoclate (8-chlorotheophyllinate), thiocyanate, triethiodide, undecanoate, undecylenate, and valerate salts.

[0018] Representative pharma- ceutically acceptable base addition salts include, but are not limited to, aluminum, 2-amino-2-(hydroxymethyl)-1,3-propanediol (tris, tromethamine), arginine, benethamine (N-benzylphenethylamine), benzathine (N,N'-dibenzylethylenediamine), bis-(2-hydroxyethyl)amine, bismuth, calcium, chloroprocaine, choline, clemizole (1-chlorobenzyl-2-pyrrolidin-1'-yl), benzoyl esters, ... These include: dimethylbenzimidazole, cyclohexylamine, dibenzylethylenediamine, diethylamine, diethyltriamine, dimethylamine, dimethylethanolamine, dopamine, ethanolamine, ethylenediamine, L-histidine, iron, isoquinoline, lepidine, lithium, lysine, magnesium, meglumine (N-methylglucamine), piperazine, piperidine, potassium, procaine, quinine, quinoline, sodium, strontium, t-butylamine, and zinc.

[0019] In some embodiments, the acid addition salt is selected from hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, nitrate, phosphate, hydrogen phosphate, acetate, benzoate, succinate, saccharate, fumarate, maleate, lactate, citrate, tartrate, gluconate, camsylate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate.In some embodiments, the base addition salt includes metal salts (e.g., sodium, potassium, aluminum, calcium, magnesium and zinc) and ammonium salts (e.g., isopropylamine, diethylamine, diethanolamine salts).Other salts (e.g., trifluoroacetate and oxalate) may be used in the preparation of the compounds and salts of the present invention and are included within the scope of the present invention.

[0020] All possible stoichiometric and non-stoichiometric forms of the salts of the compounds of the present invention are included within the scope of the present invention. Acid and base addition salts can be prepared by a skilled chemist by treating the compounds of the present invention with the appropriate acid or base in a suitable solvent, followed by crystallization and filtration.

[0021] The pharmaceutical composition of the present invention further comprises a pharma- ceutically acceptable carrier, excipient, and / or diluent. In one embodiment, the pharmaceutical composition of the present invention further comprises a pharma- ceutically acceptable excipient.

[0022] In the method of the present invention, the preferred administration route is oral and injection for subcutaneous or intramuscular delivery.Therefore, preferred pharmaceutical compositions include compositions suitable for oral administration (e.g., tablets) and compositions suitable for injection, e.g., subcutaneous or intramuscular injection.

[0023] In another aspect, the present invention discloses a method for preventing or reducing the risk of HIV infection in humans, comprising administering a compound or salt of the present invention. Pre-exposure prophylaxis (or PrEP) is when a person at risk of HIV infection takes a drug every day to reduce the chance of contracting HIV infection. PrEP has been shown to be effective in reducing the risk of infection. As used herein, "HIV" or "human immunodeficiency virus" refers to HIV-1 and / or HIV-2.

[0024] The compounds and salts of the present invention are believed to have the HIV capsid as their biological target, and thus their mechanism of action is to modify the function of the HIV capsid in one or more ways. For example, the compounds and salts of the present invention may act as capsid inhibitors.

[0025] The compounds and salts of the present invention may be used alone or in combination with other therapeutic agents. Thus, the combination therapy of the present invention comprises the administration of at least one compound or salt of the present invention and at least one other agent that may be useful in the treatment of HIV infection. The compounds and salts of the present invention and any other pharmacologic active agent or agents may be administered together or separately, and when administered separately, administration may be performed simultaneously or sequentially in any order. For example, the compounds or salts of the present invention and other agents may be formulated and administered together in a single pharmaceutical composition, or may be formulated and administered separately.

[0026] The amount of the compound of the present invention and its salt and one or more other pharmacologic active agents, and the relative timing of administration are selected to achieve a desired combined therapeutic effect. The administration of the compound of the present invention and its salt, solvate, or other pharmacologic acceptable derivatives in combination with other therapeutic agents may be (1) a unitary pharmaceutical composition containing a plurality of compounds; or (2) a combination by simultaneous administration in separate pharmaceutical compositions each containing one of the compounds. Alternatively, the combination may be administered separately in a sequential manner, where one therapeutic agent is administered first and the other is administered second, or vice versa, and different agents may be administered on different schedules, if appropriate. Such sequential administration may be close in time or distant in time. The amount of the compound of the present invention or its salt and one or more other pharmacologic active agents, and the relative timing of administration are selected to achieve a desired combined therapeutic effect.

[0027] As such, the compounds and salts of the present invention may be used in combination with one or more agents useful in the prevention or treatment of HIV. Such agents include, for example, nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors. Suitable other agents include, for example, abacavir, atazanavir, bictegravir, cabotegravir, darunavir, delavirdine, didanosine, dideoxyinosine, dolutegravir, doravirine, efavirenz, elvitegravir, emtricitabine, etavirine, fosamprenavir, fostemsavir, GSK3640254, indinavir, islatravir, lamivudine, These include lopinavir, maraviroc, nelfinavir, nevirapine, raltegravir, rilpiverine, ritonavir, saquinavir, islatravir, stavudine, tipranavir, tenofovir, tenofovir alafenamide, tenofovir disoproxil fumarate, zalcitabine, zidovudine, antibody N6LS, GSK3739937 / VH3739937, and S-648414. Additional suitable other agents include dolutegravir, lamivudine, fostemsavir, cabotegravir, maraviroc, rilpiverine, Reyataz, tenofovir, alafenamide, EfDA, doravirine, and Preziata. Further suitable other agents include dolutegravir, lamivudine, fostemsavir, and cabotegravir.Preferred agents include, for example, bictegravir, cabotegravir, dolutegravir, fostemsavir, islatravir, and lamivudine.Particularly preferred agents include, for example, bictegravir, cabotegravir, dolutegravir, fostemsavir, and lamivudine. EXAMPLES

[0028] Preparation of bicyclo[3.1.0]hexan-3-ol [ka] To a stirred solution of cyclopent-3-enol (130 g, 1545 mmol) in DCM (1200 mL) at 0-5 °C under N2 atmosphere was added a solution of diethylzinc in hexanes (1.0 M, 3091 mL, 3091 mmol) dropwise over 3 h. To the solution at 0 °C was added a solution of diiodomethane (249 mL, 3091 mmol) in DCM (300 mL) dropwise over 1 h. The reaction mixture was warmed to 27 °C and the formation of a white precipitate was observed. The mixture was stirred for 16 h. The progress of the reaction was monitored by TLC (SiO2, 20% EtOAc / pet, Rf = 0.3, UV inactive, PMA active). The reaction mixture was quenched by careful addition of saturated aqueous NH4Cl (1.5 L). The mixture was filtered through a pad of Celite. The aqueous layer was extracted with DCM (2 x 1 L). The combined organic layers were dried over anhydrous Na2SO4, filtered, and then concentrated under reduced pressure to give crude bicyclo[3.1.0]hexan-3-ol as a red liquid, 180 g. 1 H NMR (400 MHz, CDCl3) δ = 4.41 - 4.35 (m, 1H), 2.18 - 2.05 (m, 2H), 1.73 (d, J = 13.9 Hz, 2H), 1.35 - 1.25 (m, 2H), 1.21 - 1.14 (m, 1H), 0.57 - 0.43 (m, 2H). GCMS: m / z = 98.1).

[0029] Preparation of bicyclo[3.1.0]hexan-3-one [ka] To a stirred solution of bicyclo[3.1.0]hexan-3-ol (210 g, 2054 mmol) in DCM (5000 mL) at 0 °C under N2 atmosphere, Dess-Martin periodinane (954 g, 225 mmol) was added in small portions. The mixture was warmed to 27 °C and then stirred for 16 h. The progress of the reaction was monitored by TLC (SiO2, 20% acetone / hexane, Rf = 0.3, UV inactive, PMA active). The reaction mixture was filtered through a pad of Celite and the filtrate was washed with aqueous NaOH (1N, 8 × 1 L). The combined aqueous phase was extracted with DCM (5 × 1 L). The combined organic layers were dried over anhydrous Na2SO4, filtered, and then concentrated under reduced pressure (bath temperature: 20 °C) to give crude bicyclo[3.1.0]hexan-3-one as a brown liquid. The liquid was further purified by downward distillation at 70° C. to give bicyclo[3.1.0]hexan-3-one as a pale yellow viscous liquid, 125 g (62%). 1 GCMS: M / Z = 96.1.

[0030] Preparation of 2-(2,2-difluoroacetyl)bicyclo[3.1.0]hexan-3-one [ka] To a stirred solution of bicyclo[3.1.0]hexan-3-one (125 g, 1274 mmol) in THF (1500 mL) at -78 °C under N2 atmosphere was added LDA (2.0 M in THF, 0.701 L, 1402 mmol). The solution was stirred at -78 °C for 1 h. To this solution was added slowly over 30 min a solution of ethyl difluoroacetate (174 g, 1402 mmol) in THF (300 mL) maintained at a temperature of -78 °C. The reaction mixture was warmed to 27 °C and then stirred for 1 h. The progress of the reaction was monitored by TLC (SiO2, 20% acetone / hexane, Rf = 0.3, UV activity). The reaction mixture was quenched by the addition of aqueous HCl (1 N, 2000 mL). The mixture was stirred for 30 min and then extracted with EtOAc (3 x 1000 mL). The combined organic layers were washed with brine (1000 mL), dried over anhydrous Na2SO4, and filtered. The filtrate was concentrated under reduced pressure to give 2-(2,2-difluoroacetyl)bicyclo[3.1.0]hexan-3-one as a pale yellow viscous liquid, 180 g (71%). 1 H NMR (400 MHz, CDCl3) δ = 6.18 (t, J = 54.8 Hz, 1H), 2.70 - 2.62 (m, 1H), 2.35 (d, J = 19.4 Hz, 1H), 2.14 (br s, 1H), 1.26 - 1.21 (m, 1H), 1.04-1.03 (m, 1H), 0.22-0.21 (m, 1H), LCMS: M / Z = 173.17).

[0031] Preparation of ethyl 2-(3-(difluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate [ka] To a stirred solution of 2-(2,2-difluoroacetyl)bicyclo[3.1.0]hexan-3-one (180 g, 910 mmol) in ethanol (2 L) at 27° C. under N2 atmosphere was added ethyl 2-hydrazinylacetate hydrochloride (422 g, 2729 mmol) followed by sulfuric acid (20 mL, 375 mmol). The mixture was stirred for 30 min, then heated to 100° C. and stirred for 16 h. The progress of the reaction was monitored by TLC (SiO2, 20% acetone / hexane, Rf=0.3, UV active). The reaction mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc (2000 mL), washed with water (2×1 L), brine (1.0 L), dried over anhydrous Na2SO4, filtered, and then concentrated under reduced pressure. The resulting residue was subjected to silica gel column chromatography (pet.:acetone 100:0→98:2) to obtain ethyl 2-(3-(difluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate as an off-white solid, 110 g (46%). 1 H NMR (400 MHz, DMSO-d6) δ = 6.86 (t, J = 54.8 Hz, 1H), 4.93 (s, 2H), 4.14 (q, J = 7.2 Hz, 2H), 2.88 - 2.79 (m, 1H), 2.76 - 2.68 (m, 1H), 2.14 - 2.04 (m, 2H), 1.19 (t, J = 7.2 Hz, 3H), 1.10 - 1.03 (m, 1H), 0.14 (q, J = 4.3 Hz, 1H).

[0032] Preparation of ethyl 2-(3-(difluoromethyl)-5-oxo-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate [ka] To a stirred solution of ethyl 2-(3-(difluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate (110 g, 422 mmol) and Celite (395 g) in cyclohexane (3.5 L) at 0° C., pyridinium dichromate (794 g, 2110 mmol) was added in portions. Under a nitrogen atmosphere, tert-butyl hydroperoxide (355 mL, 2130 mmol) was added dropwise to the mixture over 10 min. The reaction mixture was allowed to warm to 27° C. and then stirred at that temperature for 48 h. The progress of the reaction was monitored by TLC (SiO2, 30% acetone / pet, Rf=0.4, UV active). The reaction mixture was filtered and the filter cake was extracted with EtOAc (1000 mL). The filtrate was washed with saturated aqueous Na2S2O3 (2 x 500 mL); saturated aqueous FeSO4 (300 mL); and then with brine (500 mL). The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give the crude title compound (150 g).

[0033] Preparation of ethyl 2-(3-(difluoromethyl)-4,4a-dihydrospiro[cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-5,2'-[1,3]dithiolane]-1(3bH)-yl)acetate [ka] To a stirred solution of ethyl 2-(3-(difluoromethyl)-5-oxo-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate (75 g, 269 mmol) in DCM (1500 mL) at 27 °C under nitrogen atmosphere, ethane-1,2-dithiol (43.0 mL, 511 mmol) was added followed by boron trifluoride acetic acid (72.6 mL, 511 mmol). The solution was stirred for 16 h. The progress of the reaction was monitored by TLC (SiO2, 20% acetone / Pet, Rf = 0.35, UV active). After completion, the reaction mixture was cooled to 0 °C and quenched by the addition of saturated aqueous NaHCO3 (500 mL). The mixture was extracted with DCM (2 x 1000 mL). The combined organics were washed with brine (1000 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a brown liquid. This material was subjected to silica gel column chromatography (Pet.:EtOAc 95:5 to 90:10) to give ethyl 2-(3-(difluoromethyl)-4,4a-dihydrospiro[cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-5,2'-[1,3]dithiolane]-1(3bH)-yl)acetate as an off-white solid, 80 g (74%). 1 H-NMR (400 MHz, CDCl3) δ = 6.61 (t, J = 55.2 Hz, 1H), 5.00 - 4.85 (m, 2H), 4.29 - 4.19 (m, 2H), 3.55 - 3.46 (m, 4H), 2.63 - 2.53 (m, 1H), 2.49 - 2.38 (m, 1H), 1.30 - 1.24 (m, 4H), 0.65 - 0.60 (m, 1H). LCMS M+H = 346.9.

[0034] Preparation of ethyl 2-(3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate [ka] To a stirred solution of 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione (26.3 g, 92 mmol) in DCM (20 mL) at -70 °C under N2 atmosphere was added HF-pyridine (2.460 g, 24.83 mmol). The solution was left for 30 min. To this solution was added a solution of 2-(3-(difluoromethyl)-4,4a-dihydrospiro[cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-5,2'-1,3]dithiolane]-1(3bH)-yl)ethyl acetate (10 g, 25 mmol) in DCM (20 mL). The reaction mixture was warmed to -40 °C and then stirred at that temperature for 1 h. The progress of the reaction was monitored by TLC (SiO2, 30% EtOAc / Pet, Rf = 0.3, UV inactive). The reaction mixture was quenched by the addition of saturated aqueous NaHCO3 (200 mL). The mixture was warmed to room temperature and then extracted with EtOAc (2 x 100 mL). The combined organics were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a brown solid. This material was subjected to silica gel column chromatography (Pet.: EtOAc 100:0 -> 75-25) to give ethyl 2- (3- (difluoromethyl) -5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa [3,4] cyclopenta [1,2-c] pyrazol-1-yl) acetate as a pale yellow solid, 8.5 g (91%). 1 H NMR (400 MHz, CDCl3) δ = 6.62 (t, J = 55.2 Hz, 1H), 4.82 (s, 2H), 4.30 - 4.18 (m, 2H), 2.51 - 2.37 (m, 2H), 1.42 - 1.35 (m, 1H), 1.31 - 1.23 (m, 3H), 1.14 - 1.08 (m, 1H). LCMS M+H = 293.07.

[0035] Preparation of 2-(3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid [ka] To a stirred solution of ethyl 2-(3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate (15 g, 50 mmol) in THF (17 mL) and MeOH (66 mL) at 0° C. under N2 atmosphere was added a solution of LiOH (1.788 g, 74.7 mmol) in water (66 mL). The reaction mixture was warmed to 27° C. and then stirred at that temperature for 3 h. The progress of the reaction was monitored by TLC (SiO2, 5% MeOH / DCM, Rf=0.2, UV active). After completion, the reaction mixture was concentrated under reduced pressure, diluted with water (50 mL) and washed with EtOAc (2×250 mL) to remove impurities. The aqueous layer was adjusted to pH 2-3 with aqueous HCl (1M) and then extracted with EtOAc (3×1000 mL). The combined organics were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give 2-(3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid as an off-white solid, 14 g (98%). LCMS M+H = 265.15.

[0036] Separation to obtain 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid and 2-((3bR,4aS)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid [ka] 2-(3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid (5.5 g) was dissolved in isopropanol (20 mL). The solution was subjected to SFC chiral separation in small portions as follows: Instrument = Thar 80; Column = Chiralpak IC 30 x 250 mm, 5 micron; Solvent A = supercritical CO2; Solvent B = isopropanol with 0.5% isopropylamine (v / v); Eluent composition = 70% A: 30% B; Flow rate = 65 g / min; Back pressure = 100 bar; Temperature = 30 °C; Injection volume = 2.5 mL; Detection = 220 nm. 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid was collected as a peak eluting at 7.5 min to 14 min, and 2-((3bR,4aS)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid was collected as a peak eluting at 2.7 min to 5.8 min. For each enantiomer, the resulting solution was concentrated under reduced pressure and the resulting solid was dissolved in EtOAc and then washed twice with aqueous citric acid (1M), then water, then brine. The organic solution was dried over Na2SO4, filtered, and then concentrated in vacuo to give the separated enantiomers in 80-90% recovery.

[0037] Preparation of 3-bromo-6-chloro-2-fluorobenzonitrile [ka] To a stirred solution of 3-bromo-6-chloro-2-fluorobenzaldehyde (210.0 g, 0.89 mol, 1.0 equiv.) in water (2.1 L) at room temperature was added hydroxylamine-O-sulfonic acid (175.15 g, 1.55 mol, 1.75 equiv.). The reaction mixture was heated to 50° C. and stirred for 18 h. The mixture was cooled to room temperature and stirred for 1-1.5 h. The solid was isolated by filtration and then washed with water. The wet solid was dried under vacuum at 50° C. for 12-15 h to give 3-bromo-6-chloro-2-fluorobenzaldehyde, 190.0 g (91%).

[0038] Preparation of 7-bromo-4-chloro-1-methyl-1H-indazol-3-amine [ka] To a solution of 3-bromo-6-chloro-2-fluorobenzonitrile (360.0 g, 1.55 mol, 1.0 equiv) in ethanol (1.08 L) was added methylhydrazine sulfate (1.11 kg, 7.73 mol, 5.0 equiv) followed by triethylamine (1.3 L, 9.3 mol, 6.0 equiv) at 25-35°C. The reaction mixture was heated to 110°C and maintained for 15 h (the reaction was monitored by TLC). After completion of the reaction, the mixture was cooled to room temperature. Water (3.0 L) was added and the mixture was stirred at room temperature for 1 h. The solid was isolated by filtration and washed with water. The wet solid was dried under vacuum at 50°C for 12-15 h. The crude solid was purified by column chromatography (10% EA / Hexane to 40% EA / Hexane) to give the product as a pale yellow solid. Yield: 185.0 g (46.0%).

[0039] Preparation of N-(7-bromo-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide [ka] To a solution of 7-bromo-4-chloro-1-methyl-1H-indazol-3-amine (1.40 g, 5.37 mmol) in DCM (30 mL) was added Hunig's base (3.75 mL, 21.5 mmol), then the reaction was cooled in an ice bath and methanesulfonyl chloride (1.26 mL, 16.1 mmol) was added. The reaction mixture was stirred at this temperature for 1 h (a precipitate formed). The mixture was then diluted with dichloromethane (100 mL), washed with water, 1M HCl and brine, dried (Na2SO4), filtered and concentrated in vacuo. The residue was taken up in EtOH (30 ml) and 10 ml of 20% aqueous NaOH. The resulting mixture was heated with a heat gun until it became a homogeneous solution and stirred at room temperature for 30 min. The mixture was diluted with water (80 mL) and acidified with 1N HCl (60 mL). The precipitate was filtered, washed with water and dried in vacuo to give the title product (1.5 g) as an off-white solid. 1 H NMR (500 MHz, CDCl3) δ 7.48 (d, J=7.9 Hz, 1H), 7.24 (br s, 1H), 6.95 (d, J=7.9 Hz, 1H), 4.38 (s, 3H), 3.42 (s, 3H). LC / MS (M+H) + = 337.80.

[0040] Preparation of N-(7-bromo-4-chloro-1-methyl-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide [ka] To a mixture of N-(7-bromo-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (1.3 g, 3.84 mmol) and 1-(chloromethyl)-4-methoxybenzene (0.625 mL, 4.61 mmol) in DMF (30 mL) was added cesium carbonate (1.626 g, 4.99 mmol) and the mixture was heated at 80° C. for 2 h. The mixture was poured into water (100 mL) and extracted with EtOAc (50 ml, 2×). The combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by Bioateg (0-35% EtOAc-Hexanes) to give the title product (1.5 g) as a white foam. 1H NMR (500 MHz, CDCl3) δ 7.44 (d, J=7.9 Hz, 1H), 7.31 (d, J=8.5 Hz, 2H), 6.99 (d, J=7.9 Hz, 1H), 6.84 (d, J=8.5 Hz, 2H), 4.99 (br s, 1H), 4.76 (br s, 1H), 4.40 (s, 3H), 3.80 (s, 3H), 3.01 (s, 3H).

[0041] Preparation of N-(7-amino-4-chloro-1-methyl-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide [ka] According to reference: Andersen, Jacob et al, Synlett 2005 (14), 2209-2213. To a mixture of N-(7-bromo-4-chloro-1-methyl-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide (600.0 mg, 1.308 mmol), copper(I) iodide (49.8 mg, 0.262 mmol), sodium ascorbate (518 mg, 2.62 mmol) and (1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine (46.5 mg, 0.327 mmol) in NMP (10 mL) was added a solution of sodium azide (255 mg, 3.92 mmol) in water (2.0 mL). The mixture was then sealed and heated at 120° C. in a microwave system for 2.5 hours. The mixture was then filtered through a pad of Celite and the pad was washed with EtOAc. The filtrate was poured into water (100 mL) and extracted with EtOAc (50 ml, 2×). The combined organic layers were washed with brine, dried over MgSO4, filtered and evaporated in vacuo. The residue was purified by Bioatge (5-100% EtOAc / Hexanes) to give the title product (400 mg) as an off-white solid. 1H NMR (400 MHz, CDCl3) δ 7.33 - 7.29 (m, 2H), 6.89 (d, J=7.8 Hz, 1H), 6.85 - 6.79 (m, 2H), 6.48 (d, J=7.8 Hz, 1H), 5.11 (br.s, 1H), 4.81 (br.s, 1H), 4.30 (s, 3H), 3.80 (br.s, 2H), 3.79 (s, 3H), 2.99 (s, 3H). LC / MS (M+H) + = 395.00.

[0042] Preparation of 2-amino-6-(benzyloxy)nicotinic acid [ka] A solution of 2-amino-6-chloronicotinic acid (5 g, 29 mmol) and potassium tert-butoxide (9.75 g, 87 mmol) in benzyl alcohol (97 mL) was dissolved in 120 mL of water. o C for 3 h. After cooling to ambient temperature, the very dark reaction mixture was added to water and washed with ether (×3). The aqueous layer was then acidified with 0.5 M citric acid. The tan precipitate was filtered to give the product (4.4 g, 62%) which was used in the next reaction without further purification. 1 H NMR (500 MHz, DMSO-d6) δ 12.40 (br s, 1H), 7.94 (d, J=8.55 Hz, 1H), 7.06-7.52 (m, 5H), 6.04 (d, J=8.24 Hz, 1H), 5.33 (s, 2H). LC / MS: m / z = 245.15 [M+1] + .

[0043] Preparation of N-[(6P)-7-{2-[(1S)-1-amino-2-(3,5-difluorophenyl)ethyl]-7-hydroxy-4-oxo-3H,4H-pyrido[2,3-d]pyrimidin-3-yl}-4-chloro-1-methyl-1H-indazol-3-yl]-N-[(4-methoxyphenyl)methyl]methanesulfonamide Scheme: [ka]

[0044] Step 1: To a suspension of (S)-2-((tert-butoxycarbonyl)amino)-3-(3,5-difluorophenyl)propanoic acid (5.49 g, 18.23 mmol) and 2-amino-6-(benzyloxy)nicotinic acid (4.45 g, 18.23 mmol) in acetonitrile (92 mL) at −25° C. (yellow solution) was added pyridine (9.83 mL, 122 mmol) followed by 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide ("T3P", 45.2 ml, 76 mmol). The reaction mixture (which became clear after the addition of T3P) was stirred at -25°C to 10°C for 4.5 hours, then N-(7-amino-4-chloro-1-methyl-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide (6 g, 15.19 mmol) was added and the mixture was stirred for 18 hours while warming to room temperature. The reaction mixture was diluted with ethyl acetate and washed with 1N NaOH, then water, then 0.5 M citric acid, then water, before drying over Na2SO4 and concentrating in vacuo. The resulting residue was purified on silica (330 g RediSep Gold column) using 15 CV of 0-60% ethyl acetate in hexanes followed by 10 CV of 60% EtOAc. The desired fractions were pooled and concentrated to give a pale yellow solid (8.1 g, 9.14 mmol, 60.1% yield), N-[(1S)-1-[(3P,3P)-7-(benzyloxy)-3-(4-chloro-3-{N-[(4-methoxyphenyl)methyl]methanesulfonamido}-1-methyl-1H-indazol-7-yl)-4-oxo-3H,4H-pyrido[2,3-d]pyrimidin-2-yl]-2-(3,5-difluorophenyl)ethyl]carbamoyl ester (1H,3H,4H-pyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl]carbamoyl ester (1H,3H,4H-pyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl]carbamoyl ester (1H,3H,4H-pyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl]carbamoyl ester (1H,3H,4H-pyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl) ... A mixture of tert-butyl carbamate (major) and tert-butyl N-[(1S)-1-[(3M,3M)-7-(benzyloxy)-3-(4-chloro-3-{N-[(4-methoxyphenyl)methyl]methanesulfonamido}-1-methyl-1H-indazol-7-yl)-4-oxo-3H,4H-pyrido[2,3-d]pyrimidin-2-yl]-2-(3,5-difluorophenyl)ethyl]carbamate (minor) was obtained. LC / MS: m / z = 886.25 [M+1] + .

[0045] Step 2: TFA (21.1 mL, 274 mmol) was added to a solution of (S)-(1-(7-(benzyloxy)-3-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)tert-butyl carbamate (product from step 1, 8.1 g, 9.14 mmol) in dichloromethane (45.7 mL). The mixture was stirred at room temperature for 2 hours. The resulting pale yellow solution was concentrated. The residue was taken up in ethyl acetate and then washed three times with 1N NaOH, then dried over Na2SO4, then concentrated in vacuo to give an oily residue. The residue was purified on silica gel (330 g RediSep Gold column) using a gradient of Solvent A:Solvent B 65:35 to 0:100 (2 CV) then 0:100 (9 CV); Solvent A = hexane; Solvent B = 9:9:2 hexane:ethyl acetate:MeOH. The first eluting isomer (major) was collected and concentrated in vacuo to give N-[(6P)-7-{2-[(1S)-1-amino-2-(3,5-difluorophenyl)ethyl]-7-hydroxy-4-oxo-3H,4H-pyrido[2,3-d]pyrimidin-3-yl}-4-chloro-1-methyl-1H-indazol-3-yl]-N-[(4-methoxyphenyl)methyl]methanesulfonamide (4.1 g, 5.89 mmol, 64.5% yield). 1 H NMR (500 MHz, DMSO-d6) δ 7.86 - 7.98 (m, 1 H) 7.15 - 7.37 (m, 4 H) 6.97 - 7.06 (m, 1 H) 6.70 - 6.89 (m, 4 H) 6.40 - 6.48 (m, 1 H) 4.70 - 4.88 (m, 2 H) 3.41 - 3.81 (m, 7 H) 3.20 - 3.28 (m, 1 H) 3.08 - 3.12 (m, 3 H) 2.71 - 2.79 (m, 1 H) 1.69 - 2.00 (m, 2 H). LC / MS: m / z = 696.20 [M+1] + .

[0046] Preparation of N-((S)-1-((3P)-3-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-7-hydroxy-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide [ka] To a stirred solution of N-[(6P)-7-{2-[(1S)-1-amino-2-(3,5-difluorophenyl)ethyl]-7-hydroxy-4-oxo-3H,4H-pyrido[2,3-d]pyrimidin-3-yl}-4-chloro-1-methyl-1H-indazol-3-yl]-N-[(4-methoxyphenyl)methyl]methanesulfonamide (0.926 g, 1.330 mmol) in DMF (13 ml) was added 2-((3bS,4aR)-3-(difluoromethyl)-5,5- Difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid (0.351 g, 1.330 mmol), 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate (V) ("HATU", 0.531 g, 1.397 mmol), and DIPEA (0.581 ml, 3.33 mmol) were added. The reaction mixture was stirred for 2 hours, after which the reaction mixture was diluted with water and extracted with ethyl acetate. The combined EtOAc extracts were washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude product was purified by silica gel flash chromatography using 10-100% ethyl acetate in hexanes to give N-((S)-1-((3P)-3-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-7-hydroxy-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (1.1 g, 88%) as an off-white foamy solid. LC / MS: m / z = 942.25 [M+1] + .

[0047] Example 1: Preparation of N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-4-oxo-7-(3,3,3-trifluoropropoxy)-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

change

[0048] Alternative preparation of N-(7-amino-4-chloro-1-methyl-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide [ka] Synthesis scheme: [ka]

[0049] Step 1: Preparation of 2,6-dichloro-3-nitrobenzaldehyde [ka] To a solution of sulfuric acid (H2SO4) (5.63 L, 4.5 V) in a round bottom flask at 0-5 °C, 2,6-dichlorobenzaldehyde (1.25 kg, 7.10 mol, 1.0 equiv.) was added in small portions below 15 °C. The reaction product was stirred at 0-5 °C for 30 min. A solution of freshly prepared nitration mixture [prepared from concentrated H2SO4 (0.425 L, 0.34 V) and 70% HNO3 (0.85 kg, 13.49 mol, 1.30 equiv.) at 0 °C] was added to the above reaction mixture below 10 °C [Note: The reaction is slightly exothermic (3-6 °C), so addition at lower temperatures is preferred]. The reaction mixture was stirred at 5-10 °C for 2-3 h. After completion of the reaction (monitored by TLC), it was quenched with ice-cold water (18.75 L, 15 V) below 25 °C. The reaction mass was then allowed to warm to room temperature and stirred for 2 hours. The solid was isolated by filtration and then washed with water (2.5 L, 2.0 V). Bulk residual water was removed from the solid by maintaining the vacuum filtration for 60-90 minutes. The crude wet solid was first dried in an air atmosphere and then dried in a hot air oven at 50-55°C for 10-12 hours (until the moisture content was 5.0% or less) to obtain the dried title product, 2,6-dichloro-3-nitrobenzaldehyde (1.44 kg, 92% yield) as a yellow solid. 1 H NMR (400 MHz, CDCl3): δ 10. 44 (s, 1H), 7.88 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 8.8 Hz, 1H).

[0050] Step 2: Preparation of 2,6-dichloro-3-nitrobenzonitrile [ka] (Step 2a) To a solution of DMSO (5.9 L, 5.0 V) in a round bottom flask at room temperature was added 2,6-dichloro-3-nitrobenzaldehyde (1.17 kg, 5.31 mol, 1.0 equiv.). After stirring at room temperature for 30 min, hydroxylamine hydrochloride (0.63 kg, 9.04 mol, 1.70 equiv.) was added and the reaction was stirred at room temperature for 3 h. After completion of the reaction (monitored by TLC), the reaction was quenched by the addition of ice-cold water (18.0 L, 15.0 V) added at a rate sufficient to maintain the temperature below 30° C. (Observation: solid formed upon addition of water). The reaction was stirred at room temperature for 60-90 min. The solid was isolated by filtration and washed with water (2.5 L, 2.0 V) and then with a mixture of acetone and hexane (6.0 L, ratio 1:1). Bulk residual water was removed from the solid by maintaining vacuum filtration for 60-90 min. The wet solid was first air-dried and then finally dried in a hot air oven at 50-55°C for 10-12 h (until the moisture content was 1.0% or less) to obtain the dried target product, 2,6-dichloro-3-nitrobenzaldehyde oxime (1.22 kg, 92% yield) as an off-white solid. The crude product (containing 10-20% 2,6-dichloro-3-nitrobenzonitrile) was used directly in the next step without further purification.

[0051] (Step 2b) To a stirred solution of crude oxime (prepared above, 1.13 kg, 4.80 mol, 1.0 equiv.) in DCM (9.04 L, 8.0 V) at 0-5° C., triethylamine ("TEA", 1.02 kg, 10.09 mol, 2.1 equiv.) was added. After stirring for 5 min, methanesulfonyl chloride (0.60 kg, 5.29 mol, 1.1 equiv.) was added slowly at 15° C. (Observation: Exotherm was observed during addition). The reaction was then stirred at room temperature for 30-45 min. After completion of the reaction (reaction progress was monitored by TLC; mobile phase: 20% ethyl acetate in hexanes), the reaction was diluted with water (6.78 L, 6.0 V), the organic layer was separated, and the aqueous layer was extracted with DCM (3.4 L, 3.0 V). The combined organic layers were washed with brine (5.65 L, 5.0 V), dried over Na2SO4, and concentrated under vacuum. The crude solid obtained was triturated with hexanes (4.50 L, 4.0 V) at room temperature. The wet material was dried in a hot air oven at 50-55 °C for 5-6 h to give the dry product, 2,6-dichloro-3-nitrobenzonitrile (0.95 kg, 91% yield) as a yellow solid. 1 H NMR (400 MHz, CDCl3): δ 8.07 (d, J = 8.8 Hz, 1H), 7.63 (d, J = 8.8 Hz, 1H).

[0052] Step 3: Preparation of 4-chloro-7-nitro-1H-indazol-3-amine [ka] To a stirred solution of 2,6-dichloro-3-nitrobenzonitrile (750.0 g, 3.45 mol, 1.0 equiv.) in ethanol (7.5 L, 10.0 V) at 15-20 °C, hydrazine hydrate (519.0 g, 10.36 mol, 3.0 equiv.) was added slowly while maintaining the reaction mixture below 25 °C (Observation: the addition is slightly exothermic and solids begin to form upon addition). The temperature of the reaction mixture was gradually increased to room temperature and the mixture was then stirred for 3 h (Observation: the amount of solids increases during this time). After completion of the reaction (monitored by TLC), the mixture was diluted with water (7.5 L, 10.0 V) and further stirred at room temperature for 1 h. The solid was isolated by filtration and then washed with water (2.25 L, 3.0 V). The wet solid was washed with a mixture of acetone (1.875 L, 2.5 V) and hexane (1.875 L, 2.5 V) in a 1:1 ratio. Bulk residual water was removed from the solid by maintaining vacuum filtration for 60-90 min. The wet solid was finally dried in a hot air oven at 50 °C for 7-8 h (until the moisture content reached less than 1.5%) to obtain the dried product, 4-chloro-7-nitro-1H-indazol-3-amine (549.0 g, 75% yield) as a brick-red solid. 1 H NMR (400 MHz, CDCl3): δ 10.36 (bs, 1H), 8.20 (d, J = 8.4 Hz, 1H), 7.07 (d, J = 8.40 Hz, 1H), 4.73 (bs, 2H).

[0053] Step 4: Preparation of 4-chloro-1-methyl-7-nitro-1H-indazol-3-amine [ka] To a stirred solution of 4-chloro-7-nitro-1H-indazol-3-amine (500 g, 0.42 mol, 1.0 equiv.) in DMF (5.0 L, 10.0 V) at 5-10 °C, cesium carbonate (Cs2CO3) (1.91 kg, 5.88 mol, 2.5 equiv.) was added slowly while maintaining the reaction mixture below 10 °C. After stirring for 5-10 min, dimethyl sulfate (326.3 g, 2.59 mol, 1.1 equiv.) was added while maintaining the reaction mixture below 10 °C (Note: slow addition is preferred for better regioselectivity). The reaction temperature was then gradually increased to room temperature and stirring was continued at the same temperature for another 2 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched by the addition of ice-cold water (15.0 L, 30.0 V), and the resulting mixture was then stirred at room temperature for 6-8 h. The solid was isolated by filtration and then washed with water (1.5 L, 3.0 V). The wet solid was washed with IPA (1.5 L, 3.0 V) and then hexane (1.0 L, 2.0 V). Bulk residual water was removed from the solid by maintaining the vacuum filtration for 60-90 min. The wet solid was dried in a hot air oven at 50 °C for 7-8 h (until the moisture content was less than 1.0%). The isolated material, 4-chloro-1-methyl-7-nitro-1H-indazol-3-amine (319.0 g, 60% yield), was used in the next step without further purification. 1 H NMR (400 MHz, CDCl3): δ 7.97 (d, J = 8.32 Hz, 1H), 6.97 (d, J = 8.24 Hz, 1H), 4.63 (bs, 2H), 3.96 (s, 3H).

[0054] Step 5: Preparation of N-(4-chloro-1-methyl-7-nitro-1H-indazol-3-yl)methanesulfonamide [ka] (step 5a) To a solution of 4-chloro-1-methyl-7-nitro-1H-indazol-3-amine (625.0 g, 2.76 mol, 1.0 equiv) in DCM (6.25 L, 10.0 V) at 0-5 °C, triethylamine (TEA) (837.0 g, 8.27 mol, 3.0 equiv) was added followed by 4-dimethylaminopyridine (DMAP) (20.60 g, 0.165 mol, 0.06 equiv). The reaction was stirred for 5-10 min and then methanesulfonyl chloride (MsCl) (790.0 g, 6.89 mol, 2.5 equiv) was added slowly while maintaining the reaction below 10 °C. The reaction mixture was allowed to warm to room temperature and then stirred for 1.5-2.0 h. After completion of the reaction (monitored by TLC), the mixture was diluted with water (6.25 L, 10.0 V) and then stirred at room temperature for 15 min. The organic layer was separated and the aqueous layer was extracted with DCM (6.25 L, 10.0 V). The combined organic layers were washed with brine (1.25 L, 2.0 V), dried over Na2SO4, and concentrated to give a crude solid. The solid was triturated with hexanes (1.25 L, 2.0 V) at room temperature to give the intermediate N-(4-chloro-1-methyl-7-nitro-1H-indazol-3-yl)-N-(methylsulfonyl)methanesulfonamide, which was used directly in the next step.

[0055] (ii) To a stirred solution of N-(4-chloro-1-methyl-7-nitro-1H-indazol-3-yl)-N-(methylsulfonyl)methanesulfonamide (prepared above) in ethanol (10.5 L, 20.0 V) at room temperature, 5% aqueous NaOH (4.38 L, 7.0 V) was slowly added [Note: slow addition by dropping funnel is preferred]. The reaction product was stirred at the same temperature for 3 h. After completion of the reaction (monitored by TLC) [Sample preparation for TLC analysis: acidify about 1.0 ml of sample with 2.0 N aqueous HCl to reach pH: 2-3, extract it with ethyl acetate and analyze the organic layer by TLC], the reaction product was cooled to 0-5 °C and the pH was adjusted to 2-3 by addition of 2.0 N aqueous HCl (3.13 L, 5.0 V) while maintaining the reaction temperature below 10 °C [Note: precipitation occurred upon addition of HCl and increased with stirring]. The reaction mixture was allowed to warm to room temperature and then stirred for 1.5-2.0 h. The resulting solid was isolated by filtration and then washed with water (1.25 L, 2.0 V) and then with hexane (1.25 L, 2.0 V). Bulk residual water was removed from the solid by maintaining the vacuum filtration for 60-90 min. The wet material was dried in a hot air oven at 50 °C for 6-7 h (until the moisture content was less than 1.0%) to give the dry product, N-(4-chloro-1-methyl-7-nitro-1H-indazol-3-yl)methanesulfonamide (640.0 g, 76%) as a yellow solid. 1 H NMR (400 MHz, CDCl3): δ 8.05 (d, J = 8.32 Hz, 1H), 7.32 (bs, 1H), 7.17 (d, J = 8.28 Hz, 1H), 4.15 (s, 3H), 3.45 (s, 3H).

[0056] Step 6: Preparation of N-(4-chloro-1-methyl-7-nitro-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide [ka] To a mixture of N-(4-chloro-1-methyl-7-nitro-1H-indazol-3-yl)methanesulfonamide (635.0 g, 2.08 mol, 1.0 equiv.) and 1-(chloromethyl)-4-methoxybenzene (359.0 g, 2.30 mol, 1.1 equiv.) in DMF (6.35 L, 10.0 V) at room temperature, potassium carbonate (374.7 g, 2.70 mol, 1.3 equiv.) was added. The reaction mixture was heated to 80-90 °C and maintained at that temperature for 3 h. After completion of the reaction (monitored by TLC), the mixture was poured into ice-cold water (19.05 L, 30.0 V) [Note: Gradual quenching with vigorous stirring is preferred to avoid clumping as the product precipitates]. The resulting solid was isolated by filtration and washed with water (1.90 L, 3.0 V), then the solid was washed with hexane (1.27 L, 2.0 V). Bulk residual water was removed from the solid by maintaining the vacuum filtration for 60-90 min. The isolated solid was dissolved in ethyl acetate (12.7 L, 20.0 V) and charcoal was added (63.5 g). The mixture was heated to 60-70 °C and then stirred at that temperature for 30-45 min. The mixture was filtered hot (40-50 °C) through a pad of Celite and then the Celite pad was extracted with ethyl acetate (3.17 L, 5.0 V). The combined filtrate was concentrated to dryness under reduced pressure below 50 °C. Ethyl acetate (0.635 L, 1.0 V) was added to the solid at room temperature. The resulting solid suspension was stirred for 30 min. The solid was isolated by filtration and then washed with hexane (1.27 L, 2.0 V). Residual water was removed from the solid by maintaining the vacuum filtration for 45-60 min to give the product N-(4-chloro-1-methyl-7-nitro-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide (705.0 g, 80% yield) as a yellow solid. 1 H NMR (400 MHz, CDCl3): δ 7.99 (d, J = 8.24 Hz, 1H), 7.27 (d, J = 8.68 Hz, 2H), 7.19 (d, J = 8.24 Hz, 1H), 6.80 (d, J = 8.44 Hz, 2H), 4.95-4.76 (m, 2H), 4.17 (s, 3H), 3.76 (s, 3H), 3.01 (s, 3H).

[0057] Step 7: Preparation of N-(7-amino-4-chloro-1-methyl-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide [ka] To a stirred suspension of zinc powder (540.0 g, 8.23 ​​mol, 10.0 equiv.) in a mixture of THF (3.50 L, 10.0 V) and water (7.0 L, 20.0 V) at room temperature, ammonium chloride (NH4Cl) (449.0 g, 8.23 ​​mol, 10.0 equiv.) was added. To this mixture, N-(4-chloro-1-methyl-7-nitro-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide (350 g, 0.823 mol, 1.0 equiv.) in THF (7.0 L, 20.0 V) was added. The reaction mixture was stirred at room temperature for 3-4 h. After completion of the reaction (monitored by in-process TLC / HPLC), the mixture was diluted with ethyl acetate (3.5 L, 10.0 V) and water (1.12 L, 2.5 V). The mixture was stirred for 15 min. The reaction product was filtered through a pad of Celite bed and washed with ethyl acetate (1.75 L, 5.0 V). The biphasic filtrate was collected and the phases were separated. The aqueous layer was extracted with ethyl acetate (3.50 L, 10.0 V). The combined organic layers were washed with brine (3.50 L, 10 V), dried over Na2SO4, and then concentrated in vacuo to give a crude solid. MTBE (3.25 L, 10 V) was added to the crude product and the suspension was stirred at room temperature for 30 min. The solid was isolated by filtration. Bulk residual water was removed from the solid by maintaining the vacuum filtration for 30-45 min. The wet product was dried in a hot air oven (50 °C) for 2 h to give the title product, N-(7-amino-4-chloro-1-methyl-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide (276.0 g, 85% yield) as an off-white solid. 1H NMR (400 MHz, CDCl3): δ 7.29-7.26 (m, 2H), 6.86-6.79 (m, 2H), 6.42 (d, J = 7.80 Hz, 1H), 4.99-4.70 (m, 2H), 4.25 (s, 3H), 3.77 (s, 5H), 2.98 (s, 3H).

[0058] Preparation of 2-amino-6-(3,3,3-trifluoropropoxy)nicotinic acid [ka] Synthesis scheme: [ka]

[0059] Step 1: Preparation of 2-amino-6-(benzyloxy)nicotinic acid [ka] To a stirred solution of 2-amino-6-chloronicotinic acid (200 g, 1159 mmol) in benzyl alcohol (1400 mL, 13464 mmol) at 26° C. under N2 atmosphere was added potassium tert-butoxide (390 g, 3477 mmol). The reaction mixture was heated to 120° C. and stirred at that temperature for 16 h. The progress of the reaction was monitored by TLC (SiO2, 10% MeOH in DCM, Rf=0.5). Upon completion, the reaction mixture was diluted with water (3 L) and extracted with diethyl ether (2×1000 mL). The organic layer was separated and the aqueous layer was acidified to pH 4 using aqueous citric acid (0.5 M). The precipitated solid was collected by filtration and then dried under reduced pressure to give 2-amino-6-(benzyloxy)nicotinic acid as an off-white solid (220 g, yield=72%). 1H NMR (400 MHz, DMSO-d6) δ = 12.56 - 12.32 (m, 1H), 7.97 - 7.91 (m, 1H), 7.52 - 7.41 (m, 2H), 7.38 - 7.11 (m, 5H), 6.03 (d, J = 8.5 Hz, 1H), 5.39 - 5.31 (m, 2H). LCMS purity = 93%; m / z = 245.29 (M+H).

[0060] Step 2: Preparation of methyl 2-amino-6-(benzyloxy)nicotinate [ka] To a stirred solution of 2-amino-6-(benzyloxy)nicotinic acid (220 g, 901 mmol) in DMF (2.5 L) at 26° C. under N2 atmosphere, potassium carbonate (373 g, 2702 mmol) and iodomethane (0.282 L, 4504 mmol) were added slowly. The reaction mixture was stirred at 27° C. for 16 h. The progress of the reaction was monitored by TLC (SiO2, 40% EtOAc / Pet., Rf=0.6). Upon completion, the reaction mixture was diluted with water (5 L). The precipitated solid was isolated by filtration and then dried under vacuum to give methyl 2-amino-6-(benzyloxy)nicotinate as an off-white solid (220 g, yield=92%). 1 H NMR (400 MHz, CDCl3) δ = 8.00 (d, J = 8.4 Hz, 1H), 7.42-7.40 (m, 2H), 7.39-7.35 (m, 2H), 7.34-7.31 (m, 1H), 6.01 (d, J = 8.4 Hz, 1H), 5.33 (s, 2H), 3.84 (s, 3H). LCMS purity = 97%, m / z = 259.30 (M+H).

[0061] Step 3: Preparation of methyl 2-amino-6-hydroxynicotinate [ka] To a stirred solution of methyl 2-amino-6-(benzyloxy)nicotinate (50 g, 190 mmol) in DCM (500 mL) at 26° C. under N2 atmosphere, TFA (800 mL) and triflic acid (25 mL, 282 mmol) were added slowly. The reaction mixture was stirred at 26° C. for 16 h. The progress of the reaction was monitored by TLC (SiO2, EtOAc, Rf=0.2). Upon completion, the volatiles were removed under vacuum to give the crude product. This material was triturated with diethyl ether (3×1000 mL) and the precipitated solid was then isolated by filtration. Water (2 L) was added to the solid and the mixture was then allowed to stand for 5 h. The solid was collected by filtration and washed with water. The solid was dried under vacuum to give methyl 2-amino-6-hydroxynicotinate as an off-white solid (25 g, yield=78%). 1H NMR (300 MHz, DMSO-d6) δ = 10.92-10.76 (m, 1H), 7.65 (d, J = 9.5 Hz, 1H), 7.43-6.87 (m, 2H), 5.51 (d, J = 9.5 Hz, 1H), 3.69 (s, 3H). LCMS purity = 99.32%; m / z = 169.32 (M+H). The absence of TFA and triflic acid in the product was confirmed by 19 Confirmed by F-NMR. The product was used directly in the next step without further purification.

[0062] Step 4: Preparation of methyl 2-amino-6-(3,3,3-trifluoropropoxy)nicotinate [ka] To a stirred solution of methyl 2-amino-6-hydroxynicotinate (50 g, 297 mmol) in THF (1000 mL) at 27° C. under nitrogen atmosphere was added triphenylphosphine (156 g, 595 mmol). The reaction was cooled to 0° C. and diisopropyl azodicarboxylate ("DIAD" 116 mL, 595 mmol) was added dropwise to the reaction. The solution was stirred for 30 minutes. To the solution at 0° C. was added a solution of 3,3,3-trifluoropropan-1-ol (52.4 mL, 595 mmol) in THF (200 mL). The reaction was then allowed to warm slowly to 27° C. and then stirred at that temperature for 16 hours. The progress of the reaction was monitored by TLC (SiO2, 10% EtOAc / Pet. Rf=0.5). Upon completion, the reaction mixture was diluted with water (500 mL) and extracted with EtOAc (2×500 mL). The combined organics were washed with water (500 mL) followed by a brine solution (500 mL). The organic layer was dried over anhydrous Na2SO4, filtered and then concentrated under reduced pressure to give the crude product as a yellow semi-solid (100 g). This material was purified by silica gel chromatography eluting with 5-10% EtOAc in PET. Fractions containing the desired product were pooled and concentrated under reduced pressure to give methyl 2-amino-6-(3,3,3-trifluoropropoxy)nicotinate as a yellow liquid (50 g, 60% yield). 1 H-NMR (400 MHz, CDCl3) δ: 8.01 (d, J = 8.8 Hz, 1H), 7.21-6.85 (brs, 1H), 6.04 (d, J = 8.4 Hz, 1H), 4.50 (t, J = 6.6 Hz, 2H), 3.84 (s, 3H), 2.63-2.55 (m, 2H). LCMS analysis: Column = Acquity BEH C18 (50 mm x 2.1 mm, 1.7 um); Mobile phase A = 0.05% formic acid in water; Mobile phase B = 0.05% formic acid in CAN; Gradient = time (min) / %B: 0 / 3, 0.4 / 3, 2.5 / 98, 3.4 / 98, 3.5 / 3, 4 / 3; Column temperature = 35 °C; Flow rate = 0.6 mL / min. LCMS results: Retention time = 2.03 min; Observed ion = 265.15 (M+H); LCMS purity = 93%.

[0063] Step 5: Preparation of 2-amino-6-(3,3,3-trifluoropropoxy)nicotinic acid [ka] To a stirred solution of methyl 2-amino-6-(3,3,3-trifluoropropoxy)nicotinate (50 g, 189 mmol) in tetrahydrofuran (THF) (500 mL), methanol (150 mL) and water (80 mL) at 0° C. under nitrogen atmosphere was added lithium hydroxide monohydrate (22.66 g, 946 mmol). The reaction mixture was stirred at 50° C. for 16 h. The progress of the reaction was monitored by TLC (SiO2, 50% EtOAc / Pet. Rf=0.3). Upon completion, the reaction mixture was concentrated under reduced pressure to give an aqueous residue. This residue was then acidified to pH 4 by the addition of 1N HCl. The resulting precipitate was collected by filtration and washed with water (500 mL) followed by n-hexane (400 mL) before being dried to give 2-amino-6-(3,3,3-trifluoropropoxy)nicotinic acid as an off-white solid (45 g, 90% yield). 1 H-NMR (400 MHz, DMSO-d6) δ: 12.47 (brs, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.35 (brs, 2H), 5.98 (d, J = 8.8 Hz, 1H), 4.44 (t, J = 6.1 Hz, 2H), 2.84-2.73 (m, 2H). The product was used directly in the next step without further purification.

[0064] Alternative Manufacturing of 2-Amino-6-(3,3,3-trifluoropropoxy)nicotinic acid [ka] Synthesis scheme: [ka]

[0065] Step 1: Preparation of 2-amino-6-fluoronicotinic acid [ka] A mixture of NH3 in water ("25% NH3 in H2O", 1 L, 4 V) and isopropanol (6.5 L, 26 V) at 0 °C was sparged with ammonia gas for 1 h. To the mixture in an autoclave (25 L) was added 2,6-difluoronicotinic acid (250 g, 1571 mmol). The reaction mixture was then stirred at 105 °C for 20 h. The progress of the reaction was monitored by TLC (SiO2, 80% EtOAc / Pet. Rf=0.3). Upon completion, the reaction mixture was allowed to cool to 20 °C and then concentrated under reduced pressure below 20 °C to a volume of 4-6 V (1.5 L). The residue was dissolved in water (5 L) and acidified to pH 2-3 by addition of 2N HCl (700 mL) and then stirred for 2 h. The resulting precipitate was collected by filtration, washed with water (4000 mL) and then n-hexane (5000 mL), and then dried in a vacuum oven at 50° C. to give 2-amino-6-fluoronicotinic acid as an off-white solid (250 g, 92% yield). This product was mixed with another batch of product made by the same method to give 2000 g of combined product. Residual solvent was removed from the solid by suspending the solid in toluene (10 L) and then removing the toluene by distillation. The resulting solid was dried in a vacuum oven at 60° C. for 7 days to give 2-amino-6-fluoronicotinic acid as an off-white solid (1.6 kg, 77% yield). 1 H-NMR (400 MHz, DMSO-d6) δ: 12.94 (brs, 1H), 8.17 (t, J = 8.8 Hz, 1H), 7.56 (brs, 2H), 6.25 (dd, J = 8.2, 2.8 Hz, 1H). LCMS method: Column = Acquity BEH C18 (50 mm x 2.1 mm, 1.7 um); Mobile phase A = 0.05% formic acid in water; Mobile phase B = 0.05% formic acid in acetonitrile; Gradient = time (min) / %B: 0 / 3, 0.4 / 3, 2.5 / 98, 3.4 / 98, 3.5 / 3, 4 / 3; Column temperature = 35 °C; Flow rate = 0.6 mL / min. LCMS results: Retention time = 1.24 min; observed ion = 157.04 (M+H); LCMS purity = 96%.

[0066] Step 2: Preparation of methyl 2-amino-6-fluoronicotinate [ka] To a stirred solution of 2-amino-6-fluoronicotinic acid (150 g, 961 mmol) and potassium carbonate (398 g, 2882 mmol) in DMF (1500 mL) was added iodomethane (300 mL, 4804 mmol). The reaction mixture was stirred at 27° C. for 16 h under nitrogen atmosphere. The progress of the reaction was monitored by TLC (SiO2, 30% EtOAc / Pet. Rf=0.7). Upon completion, the reaction mixture was quenched by the addition of ice-cold water (5000 mL). The resulting precipitate was collected by filtration, washed with water (2000 mL) followed by n-hexane (1000 mL) and then dried to give methyl 2-amino-6-fluoronicotinate as a brown solid (120 g, 70% yield). 1 H-NMR (400 MHz, DMSO-d6) δ: 8.20 (t, J = 8.8 Hz, 1H), 7.54 (brs, 2H), 6.29 (dd, J = 8.4, 2.8 Hz, 1H), 3.82 (m, 3H). LCMS method: Column = Acquity BEH C18 (50 mm x 2.1 mm, 1.7 um); Mobile phase A = 0.05% formic acid in water; Mobile phase B = 0.05% formic acid in acetonitrile; Gradient = time (min) / %B: 0 / 3, 0.4 / 3, 2.5 / 98, 3.4 / 98, 3.5 / 3, 4 / 3; Column temperature = 35 °C; Flow rate = 0.6 mL / min. LCMS results: Retention time = 1.55 min; Observed ion = 171.07 (M+H); LCMS purity = 96%. The product was used directly in the next step without further purification.

[0067] Step 3: Preparation of methyl 2-amino-6-(3,3,3-trifluoropropoxy)nicotinate and 3,3,3-trifluoropropyl 2-amino-6-(3,3,3-trifluoropropoxy)nicotinate [ka] To a stirred solution of methyl 2-amino-6-fluoronicotinate (25 g, 147 mmol) and 3,3,3-trifluoropropan-1-ol (15.54 mL, 176 mmol) in THF (500 mL) at 0° C. under nitrogen atmosphere, sodium hydride (60% dispersion in oil, 8.82 g, 220 mmol) was added in small portions. The reaction mixture was stirred at 0° C. for 30 min and then gradually warmed to 27° C. and stirred at that temperature for 16 h. The progress of the reaction was monitored by TLC (SiO2, 10% EtOAc / Pet. Rf=0.5). Upon completion, the reaction mixture was cooled to 0° C. and quenched with saturated aqueous NH4Cl (300 mL). The mixture was extracted with EtOAc (2×500 mL). The combined organics were washed with brine solution (200 mL), dried over anhydrous Na2SO4, filtered, and then concentrated under reduced pressure to give methyl 2-amino-6-(3,3,3-trifluoropropoxy)nicotinate as a yellow liquid (40 g). The formation of the transesterification by-product 3,3,3-trifluoropropyl 2-amino-6-(3,3,3-trifluoropropoxy)nicotinate was also observed in the reaction. LCMS method: Column = Acquity BEH C18 (50 mm x 2.1 mm, 1.7 um); Mobile phase A = 0.05% formic acid in water; Mobile phase B = 0.05% formic acid in acetonitrile; Gradient = time (min) / %B: 0 / 97, 0.4 / 97, 2.5 / 2, 3.4 / 2, 3.5 / 97, 4.0 / 97; Column temperature = 35°C; Flow rate = 0.6 mL / min. LCMS results: Retention time = 2.04 and 2.22 min; Observed ions = 265.18 and 347.29 (M+H); LCMS purity = 57% methyl 2-amino-6-(3,3,3-trifluoropropoxy)nicotinate and 15% 3,3,3-trifluoropropyl 2-amino-6-(3,3,3-trifluoropropoxy)nicotinate. This crude product mixture was mixed with two other batches (40 g and 50 g) of crude product prepared by the same method. The combined material (130 g) was purified by silica gel chromatography eluting with 10-20% EtOAc in PET.Fractions containing the desired product were pooled and concentrated under reduced pressure to give a 6:1 mixture of methyl 2-amino-6-(3,3,3-trifluoropropoxy)nicotinate and 3,3,3-trifluoropropyl 2-amino-6-(3,3,3-trifluoropropoxy)nicotinate as a pale yellow liquid (100 g, 90% yield). 1H-NMR (400 MHz, CDCl3) δ: 8.02-7.97 (m, 1H), 7.04-6.48 (m, 1H), 6.08-6.03 (m, 1H), 4.52-4.47 (m, 2H), 3.83 (s, 3H), 2.64-2.54 (m, 2H). LCMS method: Column = Acquity BEH C18 (50 mm x 2.1 mm, 1.7 um); Mobile phase A = 0.05% formic acid in water; Mobile phase B = 0.05% formic acid in acetonitrile; Gradient = time (min) / %B: 0 / 97, 0.4 / 97, 2.5 / 2, 3.4 / 2, 3.5 / 97, 4.0 / 97; Column temperature = 35 °C; Flow rate = 0.6 mL / min. LCMS results: Retention time = 2.02 and 2.21 min; Observed ions = 264.97 and 346.97 (M+H); LCMS purity = 66% methyl 2-amino-6-(3,3,3-trifluoropropoxy)nicotinate and 11% 3,3,3-trifluoropropyl 2-amino-6-(3,3,3-trifluoropropoxy)nicotinate.

[0068] Step 4: Preparation of 2-amino-6-(3,3,3-trifluoropropoxy)nicotinic acid [ka] To a stirred solution of methyl 2-amino-6-(3,3,3-trifluoropropoxy)nicotinate and 3,3,3-trifluoropropyl 2-amino-6-(3,3,3-trifluoropropoxy)nicotinate (6:1, 100 g, 310 mmol) in tetrahydrofuran (THF) (800 mL), methanol (300 mL) and water (200 mL) at 27° C. under nitrogen atmosphere was added lithium hydroxide monohydrate (37.2 g, 1552 mmol). The reaction mixture was stirred at 50° C. for 8 h. The progress of the reaction was monitored by TLC (SiO2, 50% EtOAc / Pet. Rf=0.3). Upon completion, the reaction mixture was concentrated under reduced pressure and the resulting aqueous residue was then acidified to pH 4 by addition of 1N HCl. The resulting precipitate was collected by filtration, washed with water (2000 mL) then n-hexane (1000 mL), and then dried to give 2-amino-6-(3,3,3-trifluoropropoxy)nicotinic acid as an off-white solid (80 g, 97% yield). 1 H-NMR (400 MHz, DMSO-d6) δ: 12.47 (brs, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.33 (brs, 2H), 5.99 (d, J = 8.4 Hz, 1H), 4.45 (t, J = 6.2 Hz, 2H), 2.83-2.74 (m, 2H). LCMS method: Column = Acquity BEH C18 (50 mm x 2.1 mm, 1.7 um); Mobile phase A = 0.05% formic acid in water; Mobile phase B = 0.05% formic acid in acetonitrile; Gradient = time (min) / %B: 0 / 3, 0.4 / 3, 2.5 / 98, 3.4 / 98, 3.5 / 3, 4 / 3; Column temperature = 35 °C; Flow rate = 0.6 mL / min. LCMS results: Retention time = 1.73 min; Observed ion = 251.17 (M+H); LCMS purity = 94%. The product was used directly in the next step without further purification.

[0069] Example 1: Alternative preparation of N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-4-oxo-7-(3,3,3-trifluoropropoxy)-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide [ka] Synthesis scheme: [ka] Step 1: Preparation of tert-butyl (S)-(1-(3-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-4-oxo-7-(3,3,3-trifluoropropoxy)-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate [ka] To a stirred solution of (S)-2-((tert-butoxycarbonyl)amino)-3-(3,5-difluorophenyl)propanoic acid (62.3 g, 207 mmol) and 2-amino-6-(3,3,3-trifluoropropoxy)nicotinic acid (55 g, 207 mmol) in acetonitrile (600 mL) at -25°C under nitrogen atmosphere was added pyridine (41.8 mL, 517 mmol). To the resulting mixture was added 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide ("T3P", 50% wt in EtOAc, 609 mL, 1033 mmol) dropwise over 15 min. The solution was stirred at -25°C for 1 h, then gradually warmed to 13°C and stirred for 5 h. To the solution at 13°C was added N-(7-amino-4-chloro-1-methyl-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide (82 g, 207 mmol). The reaction was then gradually warmed to 27°C and then stirred at that temperature for 16 h. The progress of the reaction was monitored by TLC (SiO2, 40% EtOAc / Pet. Rf=0.4). Upon completion, the reaction mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc (500 mL) and then washed with aqueous citric acid (0.5 M, 2 x 500 mL) followed by aqueous NaOH (1N, 3 x 500 mL). The organic layer was dried over Na2SO4, filtered and then concentrated under reduced pressure to give the crude product (180 g), which was purified by silica gel chromatography eluting with 40-50% EtOAc in pet. Fractions containing the desired product were pooled and concentrated under reduced pressure to give tert-butyl (S)-(1-(3-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-4-oxo-7-(3,3,3-trifluoropropoxy)-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate as an off-white solid (85 g, 39% yield). The product is a mixture of homochiral atropisomers (diastereomers).LCMS method: Column = Acquity BEH C18 (50 mm x 2.1 mm, 1.7 um); Mobile phase A = 0.05% formic acid in water; Mobile phase B = 0.05% formic acid in acetonitrile; Gradient = time (min) / %B: 0 / 3, 0.4 / 3, 2.5 / 98, 3.4 / 98, 3.5 / 3, 4 / 3; Column temperature = 35 °C; Flow rate = 0.6 mL / min. LCMS results: Retention time = 2.46 min; Observed ion = 892.53 (M+H); LCMS purity = 85%.

[0070] Step 2: Preparation of (S)-N-((6P)-7-((3P)-2-(1-amino-2-(3,5-difluorophenyl)ethyl)-4-oxo-7-(3,3,3-trifluoropropoxy)pyrido[2,3-d]pyrimidin-3(4H)-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide [ka] To a stirred solution of (S)-(1-(3-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-4-oxo-7-(3,3,3-trifluoropropoxy)-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)tert-butyl carbamate (85 g, 95 mmol) in DCM (300 mL) at 0° C. was added trifluoroacetic acid (TFA, 294 mL, 3810 mmol) followed by triflic acid (25.4 mL, 286 mmol). The solution was warmed to 27° C. and stirred under nitrogen atmosphere for 1 h. The progress of the reaction was monitored by TLC (SiO2, 80% EtOAc / Pet. Rf=0.3). Upon completion, the volatiles were removed under a gentle stream of nitrogen gas. The residue was dissolved in EtOAc (1000 mL) and washed with 2N NaOH (2×500 mL) followed by brine (500 mL). The organic layer was dried over Na2SO4, filtered and then concentrated under reduced pressure to give the crude product which was purified by silica gel chromatography eluting with 50-99% EtOAc in Pet. Fractions containing the desired product were pooled and concentrated under reduced pressure to give (S)-N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-4-oxo-7-(3,3,3-trifluoropropoxy)pyrido[2,3-d]pyrimidin-3(4H)-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide as a pale yellow solid (63 g). The material is a mixture of homochiral atropisomers (diastereomers) in a ratio of 64:26 as determined by LCMS. This product was mixed with three additional batches of product prepared by the same procedure below. The combined product (195 g) was dissolved in methanol:acetonitrile (80:20, 1300 mL) and this solution was purified by prep-SFC using the following method: column = (R,R) Whelk-01 (250 x 30 x 5 μ); eluent = CO2:MeOH (65:35); flow rate = 90 g / min; back pressure = 120 bar; detection = 214 nm (UV); stack time = 14 min; load per injection = 430 mg.The pure major peak was collected and concentrated under reduced pressure to give the single stereoisomer (S)—N-((6P)-7-((3P)-2-(1-amino-2-(3,5-difluorophenyl)ethyl)-4-oxo-7-(3,3,3-trifluoropropoxy)pyrido[2,3-d]pyrimidin-3(4H)-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide as an off-white solid (113 g, 63% yield). 1 HNMR (400 MHz, DMSO-d6) δ: 8.42 (d, J = 8.8 Hz, 1H), 7.43 (d, J = 8.1 Hz, 1H), 7.37 (d, J = 8.1 Hz, 1H), 7.06 (d, J = 8.8 Hz, 1H) 7.03-6.97 (m, 1H), 6.75-6.70 (m, 2H), 4.73-4.69 (m, 2H), 3.68 (s, 3H), 3.58-3.52 (m, 1H), 3.28-3.24 (m, 1H), 3.22 (s, 3H), 2.97-2.83 (m, 3H). LCMS method: Column = XBridge C18 (75 mm x 4.6 mm, 3.5 μm); Mobile phase A = 5 mM ammonium bicarbonate in water; Mobile phase B = acetonitrile; Gradient = time (min) / %B: 0 / 5, 0.5 / 5, 1.0 / 15, 4.0 / 98, 7.0 / 98, 7.5 / 5, 8.0 / 5; Column temperature = 35 °C; Flow rate = 1.3 mL / min. LCMS results: Retention time = 4.03 min; Observed ion = 672.07 (M+H); LCMS purity = 98%; HPLC purity = 98%; Chiral HPLC purity = 98%.

[0071] Step 3: Preparation of N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-4-oxo-7-(3,3,3-trifluoropropoxy)-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide [ka] To a stirred solution of (S)-N-((6P)-7-((3P)-2-(1-amino-2-(3,5-difluorophenyl)ethyl)-4-oxo-7-(3,3,3-trifluoropropoxy)pyrido[2,3-d]pyrimidin-3(4H)-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (55 g, 82 mmol) and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid (22.70 g, 86 mmol) in ethyl acetate (818 ml) was added 2,6-lutidine (23.83 ml, 205 mmol). To the mixture was added 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide ("T3P", 50% wt. in ethyl actate) (97 mL, 164 mmol) dropwise, raising the internal temperature from 17° C. to 24° C. The mixture was stirred at room temperature for 2 h. The reaction was quenched by the addition of water (500 mL). The phases were partitioned and the organic phase was washed with water (500 mL) and then dried over Na2SO4. The mixture was filtered and the filtrate was concentrated to ¼ of the original volume to give the crude product as a solution in ethyl acetate.

[0072] A second batch of product was prepared according to the same procedure with the following modification: the reaction was carried out with (S)-N-((6P)-7-((3P)-2-(1-amino-2-(3,5-difluorophenyl)ethyl)-4-oxo-7-(3,3,3-trifluoropropoxy)pyrido[2,3-d]pyrimidin-3(4H)-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (53.4 g, 79 mmol) and the amounts of all other reagents were adjusted accordingly. Workup was completed by washing with brine (300 mL) before drying over MgSO4.

[0073] The crude products were combined and then adsorbed onto Celite. The resulting powder was subjected to silica gel chromatography (3 kg RediSep Gold column) eluting with 30-85% ethyl acetate in hexanes. Fractions containing the desired product were pooled and concentrated under reduced pressure to give a yellow foam. The material was placed under high vacuum for 18 hours. The material was converted to a fine powder using a mortar and pestle and the solid was placed in a vacuum oven at 50° C. for 48 hours to give N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-4-oxo-7-(3,3,3-trifluoropropoxy)-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide as a yellow powder (134.1 g, 90% yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 9.84 - 9.91 (1 H, m) 9.49 (1 H, d, J=8.34 Hz) 8.47 (1 H, d, J=8.35 Hz) 7.79 (1 H, d, J=7.75 Hz) 7.49 (1 H, d, J=8.05 Hz) 7.11 (1 H, d, J=8.64 Hz) 6.80 - 7.09 (2 H, m) 6.66 (2 H, dd, J=8.20, 2.24 Hz) 4.69 - 4.75 (3 H, m) 4.57 (1 H, d, J=16.39 Hz) 4.48 (1 H,ddd, J=11.03, 8.35, 2.68 Hz) 3.51 (3 H, s) 3.42 (1 H, dd, J=14.01, 2.38 Hz) 3.20 (3 H, s) 3.05 (1 H, dd, J=14.01, 11.03 Hz) 2.89 - 2.99 (2 H, m) 2.42 - 2.48 (2 H, m) 1.32 - 1.40 (1 H, m) 0.81 - 0.86 (1 H, m). LCMS method: カラム=Acquity UPLC BEH C18 (2.1×100mm, 1.7um particles); solvent A=0.1%v / v acid containing, water: MeCN (95:5); solvent B=0.1%v / v The acid contains: MeCN: water (95:5); グラジエント=time (minutes) / %B: 0 / 0, 3.5 / 100, 4.5 / 100; flow rate=0.8mL / minute. LCMS results: retention time = 3.173 minutes; measurement quality = 917.95 (M+H). UPLC purity = 99.8%.

[0074] Example 1 naming: The compound of Example 1 prepared above is a homochiral material with axial chirality. The axial chirality can be described using the P / M nomenclature system detailed in the IUPAC Gold Book (doi:10.1351 / goldbook.A00547). However, at present, there are only a limited number of available software tools capable of generating chemical names with the P / M nomenclature system, and few options are available for converting chemical names using this nomenclature system into structural representations of molecules. Therefore, for clarity and convenience, some names for Example 1 are provided below:

[0075] Example 1 names generated by ChemDraw Ultra 12 (without P / M nomenclature): N-((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-4-oxo-7-(3,3,3-trifluoropropoxy)-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

[0076] Chemical names generated by JChem for Excel (including P / M nomenclature) for Example 1: N-[(1S)-1-[(3P,3P)-3-(4-chloro-3-methanesulfonamido-1-methyl-1H-indazol-7-yl)-4-oxo-7-(3,3,3-trifluoropropoxy)-3H,4H-pyrido[2,3-d]pyrimidin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2S,4R)-9-(difluoromethyl)-5,5-difluoro-7,8-diazatricyclo[4.3.0.0 2 , 4 ]Nona-1(6),8-dien-7-yl]acetamide

[0077] Chemical names generated by ChemDraw Ultra 12 with manual P / M nomenclature added: N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-4-oxo-7-(3,3,3-trifluoropropoxy)-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

[0078] Comparative Test: The compound of Example 1 was compared in a number of tests with the compound of Example 60.2 described in WO2018203235 (Scheme 1). For the purpose of these comparisons, the inventors chose to use homochiral materials of each compound, since this level of purity is most representative of that used in human clinical trials. Specifically, the restricted rotation of the indazole around the indicated C-N bond gives rise to atropisomers (diastereomers) in both Example 1 and Example 60.2 that can be separated by chromatography and do not interconvert at room temperature. Thus, using chromatography, the inventors isolated the stereoisomers shown in Scheme 2 in pure form. [ka] [ka]

[0079] General procedure for quantifying compounds by LC-MS / MS: All in vitro samples were injected into an Exion LC 4500 Triple Quad™ LC-MS / MS system. The analytical column used was a Phenomenex C18 (C18, 4.6 mm×50 mm, 5 μm) maintained at room temperature. Mobile phase A consisted of 0.1% (v / v) formic acid in MilliQ water. Mobile phase B consisted of 100% methanol. The flow rate was 1 mL / min. The gradient was as follows: mobile phase B was increased linearly from 5% to 90% over 0.7 min, held at 90% for 1.4 min, and held at 5% for 0.7 min.

[0080] All in vivo samples were injected into a Triple Quad™ 6500 LC-MS / MS system with the column maintained at 60° C. Mobile phase A consisted of HO, 1 mM NH4OAc, 0.025% formic acid. Mobile phase B consisted of MeOH, 5 mM NH4OAc. The flow rate was 0.6 mL / min. The column and elution gradient were selected from one of the general analytical methods described below.

[0081] General analysis method A : Column = Waters X-Bridge BEH C18 (2.1 x 50 mm, 1.7 μm particles); Gradient: time (min) / %B = 0.0 / 10, 0.2 / 10, 0.8 / 90, 1.3 / 90, 1.31 / 10, 2.0 / 10.

[0082] General analysis method B : Column = Waters BEH C18 (2.1 x 50 mm, 2.5 μm particles); Gradient: time (min) / %B = 0.0 / 10, 0.2 / 10, 0.8 / 90, 1.3 / 90, 1.31 / 10, 2.0 / 10.

[0083] General analysis method C : Column = Waters BEH C18 (2.1 x 50 mm, 1.7 μm particles); Gradient: time (min) / %B = 0.0 / 2, 0.40 / 2, 0.7 / 65, 1.3 / 90, 1.9 / 90, 1.91 / 2, 2.5 / 2.

[0084] Procedure for measuring potency and cytotoxicity: MT-2 cells, 293T cells and NL 4-3 Proviral DNA clones of the virus were obtained from the NIH AIDS Research and Reference Reagent Program. MT-2 cells were grown in RPMI1640 medium supplemented with 10% inactivated fetal bovine serum (FBS), 100 mg / ml penicillin G, and up to 100 units / mL streptomycin. 293T cells were grown in DMEM medium supplemented with 10% inactivated FBS, 100 mg / mL penicillin G, and 100 mg / mL streptomycin. Recombinant NL, in which a section of the nef gene was replaced with the Renilla luciferase gene, was used. 4-3 The proviral clone was used to generate the reference virus used in these studies. Recombinant NL was transfected using Transit-293 Transfection Reagent from Mirus Bio LLC (Madison, WI). 4-3 Recombinant virus was generated by transfection of the proviral clone into 293T cells. Supernatants were harvested after 2-3 days and the amount of virus present was measured in MT-2 cells by measuring luciferase enzyme activity, using luciferase enzyme activity as a marker. Luciferase was quantified using EnduRen Live Cell Substrate from Promega (Madison, WI). Antiviral activity of compounds against recombinant virus was quantified by measuring luciferase activity in MT-2 cells infected with recombinant virus for 4-5 days in the presence of serial dilutions of compound.

[0085] (Fa) = 1 / [1 + (ED 50The median effective concentration (EC) was calculated using the exponential form of the median effectiveness equation (Johnson VA, Byington RT. Infectivity Assay. In Techniques in HIV Research. ed. Aldovini A, Walker BD. 71-76. New York: Stockton Press. 1990), where EC is the effective concentration of the drug (mg / drug concentration). 50 ) was calculated. Percent inhibition = 1 / [1 + (EC 50 The 50% inhibitory concentration (EC) was calculated using the exponential form of the median effective concentration equation: [EC / drug concentration (m)], where m is a parameter reflecting the slope of the concentration-response curve. 50 ) was calculated.

[0086] The cytotoxicity of compounds and the corresponding CC were determined using the same protocol as described in the antiviral assay, except that non-infected cells were used. 50 Cytotoxicity was assessed in uninfected MT2 cells on day 4 by using an XTT (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt)-based colorimetric assay (Sigma-Aldrich, St. Louis, MO).

[0087] result: The potency of Examples 1 and 60.2 is within the margin of error of the original anti-HIV virological assay (EC 50 = 25 ± 8 pM, EC of Example 60.2 50 = 18 ± 13 pM). EC 50 Note that when first tested, it was 0.034 nM, but after further testing the mean was revised to 25 ± 8 pM. 50 are greater than 0.5 μM and greater than 10 μM in Examples 1 and 60.2, respectively.

[0088] Procedure for measuring metabolism in liver microsomes: Liver microsomes from human, rat, dog and monkey were thawed and diluted to a final concentration of 1 mg / mL in 100 mM potassium phosphate buffer (pH 7.4). Test compounds and controls were prepared in 1:1 acetonitrile:water (v / v) at a 100-fold final concentration of 1 μM and dispensed into the microsome mixture. The mixture was preincubated for 10 min at 37°C in a shaking water bath. Incubations were performed in duplicate. Three controls were included in the incubations: warfarin, phenacetin, and verapamil. After preincubation, the reaction was initiated with NADPH at a final concentration of 1 mM. At 0, 5, 15, 30, 45 and 60 min, 25 μL of sample was removed and quenched with 300 μL of acetonitrile containing the internal standard (telmisartan). Samples were vortexed at 1200 rpm for 5 min and then centrifuged at 4000 rpm for 10 min. A 100 μL aliquot of the supernatant was diluted 3-fold with water and injected onto an Exion LC 4500 Triple Quad LC-MS / MS system. Results were reported as the percentage of parent test compound remaining, calculated from the peak area ratio of remaining test compound at each time point, compared to the zero time incubation.

[0089] result: Example 1 is six times more stable in dog liver microsomes than Example 60.2, and Example 1 is at least two times more stable in monkey liver microsomes than Example 60.2. This data suggests that Example 1 should be significantly more stable than Example 60.2 to in vivo metabolism in dogs and monkeys.

[0090] [Table 1]

[0091] Procedure for measuring metabolism in human hepatocytes: Cryopreserved hepatocytes in suspension from humans, monkeys, dogs, rats and mice were thawed and diluted with pre-warmed William's Medium E (pH 7.4). An aliquot of the hepatocyte suspension was added to a test compound standard solution prepared in pre-warmed William's Medium E (pH 7.4) at 0.5 × 10 6 A final concentration of 0.5 μM in cells / milliliter and DMSO of 0.25% or less was achieved. The samples were incubated at 37° C. with 5% carbon dioxide and shaken at 200 rpm. Incubations were performed in one run. At 0, 10, 30, 60, 120 and 240 minutes, a 50 μL aliquot of the incubation mixture was removed and added to a 100 μL solution of acetonitrile containing the internal standard, the mixture was vortexed and then centrifuged at 4° C. and 3500 rpm for 15 minutes. After completion of the experiment, samples were analyzed by LC-MS / MS. Metabolic stability results were reported as the percentage of parent test compound remaining. This percentage was calculated using the t x ) by the peak area ratio of the test compound at time zero (t0) immediately before incubation. Disappearance rate constant (k, min -1 ) is calculated using nonlinear regression fitting the following equation:

number

number

number

[0092] result: The half-life of Example 1 in human hepatocytes was calculated to be over 480 minutes, while the half-life of Example 60.2 in human hepatocytes was calculated to be 350 minutes. The intrinsic clearance of Example 60.2 in human hepatocytes is 0.465 mL / min / g liver, 1.5 times faster than the clearance of 0.312 mL / min / g liver observed for Example 1.

[0093] Procedure for measuring in vivo pharmacokinetic parameters (PK): PK was studied in male CD1 mice, Wistar Han rats, cynomolgus monkeys, and beagle dogs. Two groups of animals (N=3 per group) received test compounds either intravenously (IV) (1 mg / kg) or by oral gavage (5 mg / kg solution and suspension). Drugs were formulated in 90% PEG400, 10% ethanol for IV administration and 90% PEG400, 5% ethanol for PO administration. Blood samples were collected at 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 5, 7, 24, 48, 72, and 96 hours after IV dosing and at 0.25, 0.5, 0.75, 1, 2, 3, 5, 7, 24, 48, 72, and 96 hours after oral dosing. Blood samples were collected in K3EDTA tubes and centrifuged at 1500–2000 × g to obtain plasma. Plasma samples were stored at -20°C until analysis by LC-MS / MS. All in vivo samples were injected onto an Exion LC 4500 Triple Quad™ LC-MS / MS system with the column maintained at 60°C and a flow rate of 0.6 mL / min. All LC-MS / MS analytical parameters were electronically captured into the raw data files. Rat IV, dog IV, monkey IV, and monkey PO PK samples were analyzed by generic analytical method A. Mouse IV, mouse PO, and dog PO PK samples were analyzed by generic analytical method B. Rat PO samples were analyzed by generic analytical method C.

[0094] PK parameters were obtained by noncompartmental analysis of plasma concentration versus time data (Phoenix WinNonlin v8.1). Peak concentration (C max ) and C max Arrival time (T max ) was recorded directly from experimental observations. The area under the curve from time zero to the final sampling time [AUC 0-T ] and the area under the curve from time zero to infinity [AUC INF ] was calculated using the linear-logarithmic trapezoidal method. Total plasma clearance (CL Tp ), steady-state distribution volume (V ss), apparent elimination half-life (T-HALF), and mean residence time (MRT) were estimated after IV administration. AUC and T-HALF estimations were performed using a minimum of three time points with quantifiable concentrations. Absolute oral bioavailability (F) was estimated as the ratio of dose-adjusted AUC values ​​after oral and IV administration.

[0095] result: The IV pharmacokinetic (PK) parameters of Example 1 and Example 60.2 were measured in four preclinical species: mice, rats, dogs and monkeys. Example 1 showed improved clearance in all four species compared to Example 60.2. Consistent with the results of the liver microsomal assay above, the difference in clearance was most significant in dogs and monkeys, with 4.9-fold and 2.6-fold improvements in clearance, respectively. Similarly, the half-life of Example 1 in the circulation in dogs and monkeys was 3.4-fold and 2-fold higher than Example 60.2, respectively.

[0096] [Table 2]

[0097] [Table 3]

[0098] Before a proposed drug can enter human clinical trials, the safety of a compound should generally be evaluated in two preclinical species: one rodent and one nonrodent. These species are usually rats, and either dogs or monkeys. One goal of in vivo safety testing is to achieve a concentration of the drug in the circulation that is several times higher than would be expected if a human were administered an effective dose of the drug. The fold difference between the drug concentration achieved in a safety test and the drug concentration expected in a human taking an effective dose of the drug is referred to as the "margin." It is important to achieve a high margin in safety testing, because as the margin increases, there is a greater degree of confidence that a drug-related adverse event, if it could occur, would be observed during the preclinical safety evaluation.

[0099] Improved PK parameters in rats, dogs or monkeys mean that lower doses of compound are needed to achieve high concentrations of drug in circulation for these preclinical species. Thus, monkeys or dogs receiving a dose of Example 1 are likely to achieve higher margins than those receiving the same size dose of Example 60.2. Due to practical constraints on dose size, the margins (and therefore confidence) that can be achieved with Example 1 in non-rodent safety evaluation studies are higher than those that can be achieved with Example 60.2.

[0100] Procedure for allometric scaling of preclinical PK parameters to provide predictions of human dosing: Human dose predictions were performed using Phoenix WinNonlin (v8.0) software and Microsoft Excel using the ModelRisk add-in for population modeling. Tp Human estimates for were obtained based on average allometric scaling of mouse, rat, monkey and dog IV data (body weight scaling factor 0.75) and the average of all species for Vss (body weight scaling factor 1.0). Human Vss and CL Tp Human IV parameters (Vc, Ka, K12, K21, Kel) were determined using mean residence time (MRT) scaling from preclinical species (mouse, rat, dog and cynomolgus monkey) using estimates. Absorption (Ka) was determined by deconvolution (PO) or from half-lives (SC) in preclinical species (Ka=LN(2) / t1 / 2). Predicted human doses for PO and SC are calculated to account for human variability and to cover 95% of the human population.

[0101] result: Preclinical species PK parameters are commonly used to predict human PK parameters prior to human clinical trials. The method used for this predication is called "allometric scaling" and is commonly discussed and implemented in the literature. Using allometric scaling, the predicted once-daily oral dose required to maintain an effective plasma concentration of the drug in humans is 7-fold lower in Example 1 than in Example 60.2. Specifically, the predicted human QD PO dose in Example 1 is less than 10 mg, while the predicted human QD PO dose in Example 60.2 is greater than 30 mg.

[0102] Idiosyncratic drug reactions (i.e., hypersensitivity reactions) present a significant clinical problem because of their unpredictability and severe nature, but it has been stated that drugs administered at daily doses of 10 mg or less are rarely, if ever, associated with a high incidence of idiosyncratic drug reactions (Uetrecht, JP New Concepts in Immunology Relevant to Idiosyncratic Drug Reactions: The “Danger Hypothesis” and Innate Immune System. Chem. Res. Toxicol. 1999, 12(5), 387-395, DOI:10.1021 / tx980249i).

[0103] Procedure for measuring pharmacokinetic parameters in subcutaneous in vivo experiments: Drugs were formulated in 1% Kolliphor P188 / 1% PEG3350 / 3.5% mannitol / 94.5% water and then administered to Wistar Han rats as subcutaneous injections at a dose of 20 mg / kg. Blood samples were collected at 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 5, 7, 24, 48, 72, 96 hours and then every 3 days for up to 122 days. Blood samples were collected in K3EDTA tubes and centrifuged at 1500-2000×g to obtain plasma. Plasma samples were stored at -20°C until analysis by LC-MS / MS.

[0104] result: The suitability of each compound for subcutaneous (SC) administration was evaluated in a rat SC PK study. As determined in this study, the apparent half-life of the compound in plasma was 13 days for Example 1 and 11.5 days for Example 60.2. The AUC 0-infinity was 4,941 day*ng / mL (2.89% of the extrapolated AUC). 0-infinity was 609 days*ng / mL (12.8% of the extrapolated AUC). Bioavailability was 93% for Example 1 and 25% for Example 60.2. Drug concentrations were maintained above 7ng / mL for all animals for 73 days for Example 1 and 24 days for Example 60.2 (Figure 1). Apparent half-lives and bioavailabilities derived from SC rat PK, along with predicted human clearance values ​​derived from allometric scaling, were used to calculate predicted monthly subcutaneous (Q1M SC) doses in humans. The predicted Q1M SC dose required to maintain effective plasma concentrations of the drug in humans is 15-fold lower for Example 1 than for Example 60.2.

[0105] Procedure for measuring cytochrome P450 induction in cryopreserved human hepatocytes: Following FDA guidance ("In Vitro Metabolism- and Transporter- Mediated Drug-Drug Interaction Studies Guidance for Industry"), the ability of Example 1 and Example 60.2 to induce CYP2B6 expression was tested using hepatocytes from the same three individual donors (not pooled donors) and changes in enzyme mRNA levels were assessed using the "fold change method." In this test, a fold change in mRNA levels of less than 2-fold is considered a negative finding, while a change of 2-fold or more is considered a positive finding.

[0106] Compounds were tested in a CYP induction assay using inducible cryopreserved human primary hepatocytes from three donors to determine their ability to cause induction of CYP2B6 (measured by increased mRNA transcription). Test compounds (final concentrations 0.12-30 μM) were incubated for 48 h with primary human hepatocytes that naturally express all nuclear receptors involved in regulating the expression levels of the various CYP enzymes. Fresh solutions of test compounds and controls were diluted in assay medium and added every 24 h for two consecutive days, resulting in a final DMSO concentration of 0.1%. At the end of the incubation, the integrity of the cell monolayer, cell density and viability were assessed to assess cytotoxic effects. Cells were then solubilized in cell lysis buffer and total RNA was purified from each assay sample. Samples were then used in reverse transcription polymerase chain reaction (RT-PCR) to quantify the amount of specific mRNA species encoding the human CYP2B6 gene.

[0107] The induction potency of the test compounds and controls was compared to the known CYP2B6 inducer phenobarbital (1000 μM). The results of this assay are expressed as fold induction. Fold induction was calculated as the ratio of mRNA levels in cells treated with the test compound to the basal mRNA levels in cells treated with DMSO (solvent control) alone, and thus represents the induction potency of the test compound. The fold induction values ​​were used to calculate the percent of control activity values, which were then fitted to a four-parameter logistic regression model to determine the EC 50 and E max Values ​​of CYP induction potential (if induction was observed) were determined. Cytotoxicity was also assessed in parallel to avoid false-positive CYP induction results due to cytotoxicity. Evaluation and interpretation of CYP induction potential at cytotoxic concentrations should be avoided.

[0108] result: No cytotoxicity was observed for any compound at any concentration tested (up to 30 μM). In Example 1, negative findings (no induction) were observed in all three donors. In Example 60.2, positive findings (induction) were observed in two of three donors (ECs of 1.5 μM and 1.8 μM). 50value).

[0109] Induction of CYP enzyme expression is recognized as a root cause of drug-drug interactions leading to increased clearance of victim drugs whose metabolism is dominated by the induced CYP isoforms. Of the CYP isoforms, CYP2B6 is of particular importance in the context of HIV treatment because efavirenz (EFV), a drug widely used in the treatment of HIV (included in the 2019 World Health Organization Essential Medicines List), is primarily metabolized by CYP2B6 (Ward, BA, Gorski, JC, Jones, DR, Hall, SD, Flockhard, DA, Desta, Z. The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV / AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity, J. Pharmacol. Exp. Ther., 2003, 306, 287-300, DOI: 10.1124 / jpet.103.049601).

Claims

1. Compound: 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof.

2. The compound of claim 1 having the stereochemistry shown below 【Chemistry 2】 or a pharma- ceutically acceptable salt thereof.

3. The compound of claim 2 having the stereochemistry shown below 【Chemistry 3】 or a pharma- ceutically acceptable salt thereof.

4. A pharmaceutical composition comprising a compound or salt according to any one of claims 1 to 3.

5. The composition of claim 4 further comprising a pharma- ceutically acceptable excipient.

6. 6. The composition of claim 4 or claim 5, which is suitable for oral administration, intramuscular injection, or subcutaneous injection.

7. A composition according to any one of claims 4 to 6 for use in the treatment of HIV infection in humans.

8. 8. The composition of claim 7 for use in combination with at least one other agent used in the treatment of HIV infection in humans.

9. 9. The composition of claim 8, wherein the at least one other agent is selected from the group consisting of abacavir, atazanavir, bictegravir, cabotegravir, dolutegravir, darunavir, doravirine, fostemsavir, lamivudine, maraviroc, rilpiverine, tenofovir disoproxil, tenofovir, tenofovir alafenamide, S-648414, GSK3640254, antibody N6LS, and GSK3739937 / VH3739937.

10. 10. The composition of claim 9, wherein the at least one other agent is selected from the group consisting of dolutegravir, lamivudine, fostemsavir, cabotegravir, antibody N6LS, and GSK3739937 / VH3739937.

Images